-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $17

Benzinga·11/05/2026 19:46:05
RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and lowers the price target from $20 to $17.